These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20519346)

  • 1. Recombinant human thyrotropin-stimulated radioiodine therapy of nodular goiter allows major reduction of the radiation burden with retained efficacy.
    Fast S; Hegedüs L; Grupe P; Nielsen VE; Bluhme C; Bastholt L; Bonnema SJ
    J Clin Endocrinol Metab; 2010 Aug; 95(8):3719-25. PubMed ID: 20519346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioiodine 131I treatment for large nodular goiter: recombinant human thyrotropin allows the reduction of radioiodine 131I activity to be administered in patients with low uptake.
    Ceccarelli C; Antonangeli L; Brozzi F; Bianchi F; Tonacchera M; Santini P; Mazzeo S; Bencivelli W; Pinchera A; Vitti P
    Thyroid; 2011 Jul; 21(7):759-64. PubMed ID: 21568727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human thyrotropin markedly changes the 131I kinetics during 131I therapy of patients with nodular goiter: an evaluation by a randomized double-blinded trial.
    Nielsen VE; Bonnema SJ; Boel-Jørgensen H; Veje A; Hegedüs L
    J Clin Endocrinol Metab; 2005 Jan; 90(1):79-83. PubMed ID: 15494456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.
    Nieuwlaat WA; Hermus AR; Ross HA; Buijs WC; Edelbroek MA; Bus JW; Corstens FH; Huysmans DA
    J Nucl Med; 2004 Apr; 45(4):626-33. PubMed ID: 15073259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of goiter volume reduction after 0.3 mg recombinant human thyrotropin-stimulated radioiodine therapy in patients with a very large goiter: a double-blinded, randomized trial.
    Bonnema SJ; Nielsen VE; Boel-Jørgensen H; Grupe P; Andersen PB; Bastholt L; Hegedüs L
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3424-8. PubMed ID: 17566091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prestimulation with recombinant human thyrotropin (rhTSH) improves the long-term outcome of radioiodine therapy for multinodular nontoxic goiter.
    Fast S; Nielsen VE; Grupe P; Boel-Jørgensen H; Bastholt L; Andersen PB; Bonnema SJ; Hegedüs L
    J Clin Endocrinol Metab; 2012 Aug; 97(8):2653-60. PubMed ID: 22577172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter.
    Huysmans DA; Nieuwlaat WA; Erdtsieck RJ; Schellekens AP; Bus JW; Bravenboer B; Hermus AR
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3592-6. PubMed ID: 11061507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioiodine therapy in non-toxic multinodular goitre. The possibility of effect-amplification with recombinant human TSH (rhTSH).
    Bonnema SJ; Nielsen VE; Hegedüs L
    Acta Oncol; 2006; 45(8):1051-8. PubMed ID: 17118838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single, very low dose (0.03 mg) of recombinant human thyrotropin (rhTSH) effectively increases radioiodine uptake in the I-131 treatment of large nontoxic multinodular goiter.
    Mojsak MN; Abdelrazek S; Szumowski P; Rogowski F; Sykała M; Kostecki J; Kociura-Sawicka A; Jurgilewicz D; Myśliwiec J
    Nucl Med Rev Cent East Eur; 2016; 19(1):3-11. PubMed ID: 26841373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing 131I uptake after rhTSH stimulation in patients with nontoxic multinodular goiter: evidence from a prospective, randomized, double-blind study.
    Fast S; Nielsen VE; Grupe P; Bonnema SJ; Hegedüs L
    J Nucl Med; 2009 May; 50(5):732-7. PubMed ID: 19403877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter.
    Nieuwlaat WA; Huysmans DA; van den Bosch HC; Sweep CG; Ross HA; Corstens FH; Hermus AR
    J Clin Endocrinol Metab; 2003 Jul; 88(7):3121-9. PubMed ID: 12843153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified-release recombinant human TSH (MRrhTSH) augments the effect of (131)I therapy in benign multinodular goiter: results from a multicenter international, randomized, placebo-controlled study.
    Graf H; Fast S; Pacini F; Pinchera A; Leung A; Vaisman M; Reiners C; Wemeau JL; Huysmans D; Harper W; Driedger A; de Souza HN; Castagna MG; Antonangeli L; Braverman L; Corbo R; Düren C; Proust-Lemoine E; Edelbroek MA; Marriott C; Rachinsky I; Grupe P; Watt T; Magner J; Hegedus L
    J Clin Endocrinol Metab; 2011 May; 96(5):1368-76. PubMed ID: 21346067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human TSH increases the efficacy of a fixed activity of radioiodine for treatment of multinodular goitre.
    Cubas ER; Paz-Filho GJ; Olandoski M; Goedert CA; Woellner LC; Carvalho GA; Graf H
    Int J Clin Pract; 2009 Apr; 63(4):583-90. PubMed ID: 18803554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of administering 0.2 mg of recombinant human TSH for two consecutive days as an adjuvant to therapy with low radioiodine doses in elderly out-patients with large nontoxic multinodular goiter.
    Giusti M; Cappi C; Santaniello B; Ceresola E; Augeri C; Lagasio C; Minuto F
    Minerva Endocrinol; 2006 Sep; 31(3):191-209. PubMed ID: 17213787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human thyrotropin-stimulated radioiodine therapy of large nodular goiters facilitates tracheal decompression and improves inspiration.
    Bonnema SJ; Nielsen VE; Boel-Jørgensen H; Grupe P; Andersen PB; Bastholt L; Hegedüs L
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3981-4. PubMed ID: 18664541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter: a prospective randomized double-blind trial.
    Nielsen VE; Bonnema SJ; Boel-Jørgensen H; Grupe P; Hegedüs L
    Arch Intern Med; 2006 Jul; 166(14):1476-82. PubMed ID: 16864757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres.
    Silva MN; Rubió IG; Romão R; Gebrin EM; Buchpiguel C; Tomimori E; Camargo R; Cardia MS; Medeiros-Neto G
    Clin Endocrinol (Oxf); 2004 Mar; 60(3):300-8. PubMed ID: 15008994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 30-year perspective on radioiodine therapy of benign nontoxic multinodular goiter.
    Bonnema SJ; Hegedüs L
    Curr Opin Endocrinol Diabetes Obes; 2009 Oct; 16(5):379-84. PubMed ID: 19623060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High prevalence of side effects after recombinant human thyrotropin-stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/clinical hyperthyroidism.
    Romão R; Rubio IG; Tomimori EK; Camargo RY; Knobel M; Medeiros-Neto G
    Thyroid; 2009 Sep; 19(9):945-51. PubMed ID: 19678745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of radioiodine therapy in benign nodular goitre.
    Bonnema SJ; Fast S; Hegedüs L
    Best Pract Res Clin Endocrinol Metab; 2014 Aug; 28(4):619-31. PubMed ID: 25047210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.